ArticleJournal of diabetes investigation2026
Temporal distribution of acute kidney injury-related hospitalizations after initiation of sodium-glucose cotransporter 2 inhibitors: A nationwide claims database analysis in older adults with an independent complementary single-center eGFR analysis.
Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIMS/
introductionSodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce the risk of acute kidney injury (AKI). However, an initial decline in estimated glomerular filtration rate (eGFR) may occur after initiation, and factors associated with sustained early eGFR decline remain unclear. We evaluated the temporal distribution of AKI-related hospitalizations in older adults using claims data and, in an independent single-center cohort, factors associated with sustained early eGFR decline. MATERIALS AND
methodsA Japanese nationwide claims database identified patients aged ≥75 years emergently hospitalized with AKI after SGLT2i initiation. Intervals were categorized as 1-30, 31-90, and 91-180 days. Baseline characteristics were compared across groups, followed by adjusted comparisons of the 1-30-day group with each later group. An independent single-center analysis without age restriction evaluated early eGFR changes and associated factors as indirect complementary evidence.
resultsAmong 190 patients, 59 (31.1%) were hospitalized within 1-30 days, 67 (35.3%) within 31-90 days, and 64 (33.7%) within 91-180 days. After inverse-probability-of-treatment weighting, all propensity-score covariates were balanced, and no additionally adjusted medication-related factor was associated with 1- to 30-day-group assignment. Sustained early eGFR decline was associated with older age and use of one or two triple-whammy (TW)-related drug classes.
conclusionsA substantial proportion of AKI-related hospitalizations occurred within 30 days after SGLT2i initiation. In the single-center analysis, sustained early eGFR decline was associated with older age and TW-related drug use. These hypothesis-generating findings require cautious interpretation because the case-only design precludes estimation of early AKI risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.